Drugs / Telitacicept
Telitacicept
Trials 55 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06549959 | Aug → Nov 2024 overdue | — | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05687526 | May 2023 → Nov 2025 | pediatric systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05247203 | May 2022 → Oct 2023 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04235933 | Sep → Dec 2019 | — | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06656962 | Oct 2024 → Dec 2025 overdue | pauci-immune glomerulonephritis with ANCA | Renmin Hospital of Wuhan University | Active not recruiting | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT07687134 | Jul 2026 overdue | thrombocytopenia due to immune destruction | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07522099 | May 2026 → Jul 2028 expected | IgA glomerulonephritis, complement 3 glomerulopathy, membranoproliferative glomerulonephritis | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07340463 | Dec 2025 → Jun 2027 expected | lupus nephritis, systemic lupus erythematosus | Nanjing University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07111338 | Jul 2025 → May 2027 expected | proliferative glomerulonephritis | Peking University First Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06375005 | Jan 2025 → Jan 2027 expected | diffuse cutaneous systemic sclerosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06614985 | Oct 2024 → Oct 2026 expected | idiopathic membranous glomerulonephritis | Renmin Hospital of Wuhan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05998759 | Dec 2023 → Dec 2025 overdue | connective tissue disorder, thrombocytopenia | Beijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06315530 | Dec 2023 → Apr 2025 | primary antiphospholipid syndrome | Ruijin Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05929248 | Jul 2023 → Jun 2024 | systemic lupus erythematosus | Guanmin Gao | Unknown | No outcome recorded |
| Phase 2 | NCT05680480 | Apr 2023 → Dec 2025 overdue | lupus nephritis | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04905212 | Nov 2021 → Nov 2023 | IgA glomerulonephritis | RemeGen Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05078710 | Jul 2021 → Jul 2022 | antiphospholipid syndrome | Peking Union Medical College Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT04625153 | May 2021 → Apr 2026 | relapsing-remitting multiple sclerosis | RemeGen Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT04302103 | Jul 2020 → Jan 2022 | generalized myasthenia gravis | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04291781 | Apr 2020 → May 2021 | IgA glomerulonephritis | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04078386 | Nov 2019 → Jun 2021 | Sjogren syndrome | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02885610 | Dec 2015 → Jun 2019 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02882087 | Oct 2015 → Feb 2019 | rheumatoid arthritis | RemeGen Co., Ltd. | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07355257 | Feb → Dec 2026 expected | myositis disease | Zhongming Qiu | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05596708 | Mar 2023 → Jun 2025 overdue | IgA glomerulonephritis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT07495033 | Apr 2026 → May 2029 expected | interstitial lung disease | RemeGen Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07404865 | Feb 2026 → Dec 2028 expected | Sjogren syndrome | Vor Biopharma | Recruiting | No outcome recorded |
| Phase 3 | NCT07249632 | Jan → Dec 2026 expected | ocular myasthenia gravis | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07052981 | Aug 2025 → Jun 2027 expected | IgA glomerulonephritis, immune complex mediated vasculitis | Guixia Ding | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06456567 | Sep 2024 → Jan 2025 | systemic lupus erythematosus | Vor Biopharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT07098897 | Aug 2024 → May 2025 overdue | IgA glomerulonephritis | The Affiliated Hospital of Xuzhou Medical University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06456580 | Jul 2024 → May 2027 expected | generalized myasthenia gravis | Vor Biopharma | Recruiting | No outcome recorded |
| Phase 3 | NCT06125405 | Nov 2023 → Oct 2026 expected | nephrotic syndrome | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05799287 | Apr 2023 → Jun 2026 overdue | IgA glomerulonephritis | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05673993 | Apr 2023 → Oct 2024 | Sjogren syndrome | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05737160 | Mar 2023 → Nov 2024 | generalized myasthenia gravis | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05339217 | Feb 2023 → Jul 2025 | systemic lupus erythematosus | Liu Tian | Unknown | No outcome recorded |
| Phase 3 | NCT05306574 | Jun 2022 → Jan 2025 | systemic lupus erythematosus | Vor Biopharma | Terminated | No outcome recorded |
| Phase 3 | NCT04082416 | Oct 2019 → Apr 2022 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03330418 | Jan 2018 → Apr 2026 | neuromyelitis optica | RemeGen Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03016013 | Mar 2017 → Nov 2022 | rheumatoid arthritis | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07643038 | Jul 2026 → Jul 2029 expected | rheumatoid arthritis-associated interstitial lung disease | Chinese SLE Treatment And Research Group | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07077486 | Aug 2025 → Oct 2026 expected | interstitial lung disease, systemic lupus erythematosus | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07008196 | Jun → Dec 2025 overdue | rheumatoid arthritis | Chinese SLE Treatment And Research Group | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06723548 | Dec 2024 → Dec 2025 overdue | myasthenia gravis | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06546540 | Jun 2024 → Dec 2025 overdue | systemic sclerosis | Peking University Third Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05962840 | Jun 2023 → Dec 2026 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | Chinese SLE Treatment And Research Group | Recruiting | No outcome recorded |
| Phase 4 | NCT05965284 | Mar 2023 → Dec 2025 overdue | anti-neutrophil cytoplasmic antibody-associated vasculitis | Chinese SLE Treatment And Research Group | Recruiting | No outcome recorded |
| Phase 4 | NCT05666336 | Dec 2022 → Jun 2024 | systemic lupus erythematosus | Fen Li | Unknown | No outcome recorded |
| Phase 4 | NCT05899907 | Sep 2022 → Mar 2025 | systemic lupus erythematosus | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07298928 | Mar 2026 → Dec 2028 expected | — | The Children's Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07597733 | Sep 2025 → Aug 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy | Sichuan Academy of Medical Sciences | Active not recruiting | No outcome recorded |
| — | NCT06827587 | Feb 2025 → Feb 2026 overdue | generalized myasthenia gravis, neuromuscular disease | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06654596 | Dec 2024 → Dec 2026 expected | IgA glomerulonephritis | Ruijin Hospital | Recruiting | No outcome recorded |
| — | NCT06394063 | Jun 2024 → Jun 2027 expected | systemic lupus erythematosus | RenJi Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06677801 Comparator | Oct 2024 → Oct 2026 expected | systemic lupus erythematosus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | telitacicept | “BACKGROUND: Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with...” PMID 41092329 ↗ Oct 202548“Telitacicept, a TACI-Fc fusion protein, dual-targets BAFF and APRIL, inhibiting B cell and plasma cell function and reducing autoantibody production, potentially providing...” NCT07687134 ↗ “Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.” PMID 38129117 ↗ Mar 2024 “A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.” PMID 38726639 ↗ May 2024 |
| Known as | RC18 | “This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of...” NCT04905212 ↗9“Telitacicept (RC18) is a recombinant TACI-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby...” NCT07111338 ↗ |
| Known as | Tai Ai | “Tai Ai(RC18) 80mg” NCT04235933 ↗ |
| Action | Inhibit | “a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand” PMID 38129117 ↗ Mar 2024 |
| Modality | Protein / enzyme biologic | “recombinant human B lymphocyte stimulating factor receptor-antibody fusion protein” NCT02882087 ↗ |
| Route | Subcutaneous | “Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.” NCT02882087 ↗ |